Octopus is a trial which will test multiple treatments at different times with the aim to find one that can slow down, and ultimately stop, the progression of disability in participants with Progressive MS.
This will be done by initially testing “repurposed” treatments over a number of years using the MAMS trial method. By using the multi-arm, multi-stage approach with new arms added with other repurposed or novel treatments, when appropriate, it aims to be a more efficient trial. The treatments tested will largely be focused on the broad mechanisms of neuroprotection and remyelination.
Octopus plans to open to recruitment later in the year (2022) and will be available for people with Progressive MS in the UK.